Semler Scientific Secures $500M to Accelerate Breakthroughs in Cardiovascular Diagnostics

Semler Scientific, Inc. is thrilled to announce a landmark funding milestone after raising $500,000,000 in its latest financing round. This significant capital injection will accelerate the company’s mission to deliver innovative technology solutions that enhance the clinical effectiveness and efficiency of healthcare providers. Since its inception, Semler Scientific has been at the forefront of transforming chronic disease evaluation and treatment, and this funding round further solidifies its position as a pioneer in the healthcare technology arena. The company, renowned for its patented and FDA-cleared product launched in 2011, later advanced its innovation with FDA 510(k) clearance in 2015 for QuantaFlo®. QuantaFlo® is a state-of-the-art rapid point-of-care test designed to measure arterial blood flow in the extremities—a critical diagnostic tool aiding the identification of cardiovascular diseases. With these new funds, Semler Scientific is poised to expand its research and development capabilities, enhance its manufacturing infrastructure, and explore new market opportunities to cater to a broader spectrum of clinical needs. The investment will also support further product enhancements and the rollout of additional FDA-cleared diagnostic tools, strengthening the company’s commitment to improving patient outcomes through early and accurate diagnosis. Semler Scientific’s vision of revolutionizing chronic disease management with cutting-edge technology is more attainable than ever, as it continues to partner with healthcare providers around the globe and drive meaningful advancements in medical diagnostics and treatment. This funding milestone marks an exciting new chapter in the evolution of healthcare technology, underscoring the company’s dedication to fostering innovation and delivering measurable clinical impact for years to come.